Nav: Home

Science News | Science Current Events | Brightsurf | November 09, 2019


Some people with RA treated with immune checkpoint inhibitors for cancer have flare, most able to continue treatment
A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.
Live zoster vaccine safe and effective for people taking TNF inhibitors
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications (Abstract # 824).
Study points to new weapon in fight against lethal fungi
Researchers at Australia's Monash University have gained insights into how nanoparticles could develop a biosensor to prevent deadly diseases contracted on medical equipment, such as catheters.
Down syndrome arthropathy diagnosis delayed a year, optimal treatments still unclear
A new study found that patients with Down syndrome arthropathy continue to have an approximate year-long delay in diagnosis from the onset of their symptoms, and that optimal therapy for this condition remains unclear (Abstract # 2722).
Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.
Biologics offer similar disease activity improvement for elderly & young-onset RA patients
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, both patients with rheumatoid arthritis whose disease onset occurred at an older age and those whose disease onset occurred earlier in life have similar improvements in clinical disease at 48 weeks after starting biologic disease-modifying antirheumatic drugs, as well as similar drug maintenance and adverse events discontinuation rates.
SLE Medicaid patients have higher 30-day death rate compared to those with diabetes
New research found that the 30-day death rate for Medicaid patients with systemic lupus erythematosus (SLE) who underwent coronary revascularization procedures for cardiovascular disease was double that of patients with diabetes mellitus who underwent the same procedures.
Common muscle relaxant causes severe confusion in patients with kidney disease
One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after being prescribed a common muscle relaxant.
Children with Down syndrome at increased risk for inflammatory, erosive arthritis
A new study finds that children with Down syndrome are at an increased risk of an associated form of arthritis.
Hospitalizations among dialysis patients are higher in areas with more black residents
Patients receiving hemodialysis at facilities located in residential areas with a high percentage of Black residents have a higher rate of hospitalization.
Examining muscle relaxant dose, risk of encephalopathy in patients with CKD
Whether a higher or lower dose of the muscle relaxant baclofen was associated with 30-day risk of hospitalization with encephalopathy (defined as a main diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack or an unclear diagnosis of dementia) among newly prescribed patients with chronic kidney disease was the focus of this observational study with nearly 16,000 older adults.
Tocilizumab more effective than Rituximab in RA patients with low B-cell levels
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor (TNFi) inhibitors first.
Post-market price changes alone account for most recent spending growth for biologics
New research findings presented at the 2019 ACR/ARP Annual Meeting found that annual spending on biologic DMARDS (biologics) by US public programs and beneficiaries nearly doubled from 2012 to 2016.
Ultrasound to guide treatment strategy not beneficial in early RA
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, a treatment strategy guided by ultrasound information use does not appear to provide better treatment decisions in patients with early rheumatoid arthritis.
ADA2 is a specific biomarker for MAS in systemic JIA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, adenosine deaminase 2 (ADA2) in the peripheral blood is a sensitive, specific biomarker for macrophage activation syndrome, a potentially life-threatening complication of systemic juvenile idiopathic arthritis (systemic JIA).
Rising rates of kidney injury in women who are hospitalized during pregnancy
Rates of kidney injury in women who are hospitalized during pregnancy are on the rise, especially in women with diabetes.
Atmospheric and environmental changes impact organ-specific lupus flares
New research findings presented at the 2019 ACR/ARP Annual Meeting found a strong association between changes in atmospheric and environmental variables 10 days before a clinic visit and organ-specific lupus flares in patients with systemic lupus erythematosus.
Opioids offer minor pain relief and function benefits, but no quality of life benefit
New research presented at the 2019 ACR/ARP Annual Meeting suggests that opioids contribute no measurable benefit to quality of life or depression for patients with osteoarthritis (OA).
Babies exposed to TNFi or tofacitinib in utero experience very few serious infections
A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.
Physicians should consider HCQ to reduce the risk of recurrent congenital heart block
New research findings presented at the 2019 ACR/ARP Annual Meeting discovered that hydroxychloroquine (HCQ) significantly reduces the recurrence rate of congenital heart block in subsequent pregnancies of women with anti-SSA/ Ro antibodies, regardless of their health status.
Limited access to SLE lab tests in developing nations affects usefulness
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, supportive laboratory assays to diagnose lupus, specifically the antinuclear antibody (ANA) test, are less often offered in developing nations due to a relative lack of resources.
Opioid use hospitalization rates increased for patients with common rheumatic diseases
New research findings presented this week at the 2019 ACR/ARP Annual Meeting show an increase in opioid-use disorder (OUD) hospitalizations among patients with five musculoskeletal conditions, trends that healthcare providers, policy makers and patients need to be more aware of to help prevent opioid use disorder-related morbidity and mortality.
Gadolinium-enhanced MRI improves diagnostic accuracy and predicts polymyalgia rheumatica
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.
Low-dose oral prednisolone substantially improves pain and function in hand OA
Research presented at the 2019 ACR/ARP Annual Meeting found that a six-week treatment with low-dose oral prednisolone substantially improves pain and decreases signs of inflammation in patients with painful hand osteoarthritis.
Additional medications to treat children with JIA are urgently needed
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis (JIA), despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).
Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Manoush's Favorites: Moving Forward
We're hard at work on new episodes of the TED Radio Hour, which will start rolling out in March. In the meantime, new host Manoush Zomorodi shares some of her favorite episodes of the show. This episode originally aired on June 21, 2019. When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#551 Translating Science, Part 2
This week on Science for the People, we're discussing how Siksika become one of the official translation languages for press releases from the Laser Interferometer Gravitational-Wave Observatory (LIGO). The area of the world that is now known as Canada has an abundance of distinct languages; according to the 2016 Census, over 70 are still spoken. But the British government, and then the Canadian government, spent generations trying to prevent children from learning these languages. One of the languages spoken in the prairies is Siksika, also called Blackfoot (the English translation). Host Marion Kilgour speaks to Sharon Yellowfly and Corey Gray...
Now Playing: Radiolab

The Other Latif: Episode 2
The Other Latif Radiolab's Latif Nasser always believed his name was unique, singular, completely his own. Until one day when he makes a bizarre and shocking discovery. He shares his name with another man: Abdul Latif Nasser, detainee 244 at Guantanamo Bay. The U.S. government paints a terrifying picture of The Other Latif as Al-Qaeda's top explosives expert, and one of the most important advisors to Osama bin Laden. Nasser's lawyer claims that he was at the wrong place at the wrong time, and that he was never even in Al-Qaeda. This clash leads Radiolab's Latif into a years-long investigation, picking apart evidence, attempting to separate fact from fiction, and trying to uncover what this man actually did or didn't do. Along the way, Radiolab's Latif reflects on American values and his own religious past, and wonders how his namesake, a fellow nerdy, suburban Muslim kid, may have gone down such a strikingly different path.   Episode 2: Morocco Latif travels to Abdul Latif's hometown of Casablanca, Morocco, to try and find out: was he radicalized? And if so, how? Latif begins by visiting the man's family, but the family's reaction to him gets complicated as Latif digs for the truth. He finds out surprising information on a political group Abdul Latif joined in his youth, his alleged onramp to extremism. Tensions escalate when Latif realizes he's being tailed.  Read more about Abdul Latif Nasser at the New York Times' Guantanamo Docket.  This episode was produced by Sarah Qari, Suzie Lechtenberg, and Latif Nasser. With help from Tarik El Barakah and Amira Karaoud. Fact checking by Diane Kelly and Margot Williams. Editing by Jad Abumrad and Soren Wheeler. Original music by Jad Abumrad, Alex Overington, and Amino Belyamani.